GENENTECH  GENE FILES SUIT AGAINST FDA SOUTH SAN FRANCISCO MARCH 6 GENENTECH INC SAID IT FILED A SUIT AGAINST THE FOOD AND DRUG ADMINISTRATION IN THE US DISTRICT COURT FOR THE DISTRICT OF COLUMBIA OVER AN UNRESOLVED ISSUE RELATING TO GENETICALLY ENGINEERED HUMAN GROWTH HORMONE AT ISSUE SAID GENENTECH IS WHETHER ELI LILLY AND CO'S  ELI RECOMBINANT HUMAN GROWTH HORMONE AND ITS NEW RECOMBINANT GROWTH HORMONE ARE THE SAME DRUG BOTH DRUGS ARE UNDER REVIEW BY THE FDA SINCE 1985 GENENTECH HAS BEEN MARKETING PROTROPIN A RECOMBINANT HUMAN GROWTH HORMONE FOR TREATING ABNORMALLY SHORT CHILDREN THE BIOTECHNOLOGY CONCERN SAID IT HAS THE RIGHT TO SEVEN YEARS OF EXCLUSIVE MARKETING FOR PROTROPIN GRANTED ORPHAN DRUG STATUS BY THE FDA ORPHAN DRUGS ARE A SPECIAL CATEGORY OF DRUGS THAT ARE USED TO TREAT RARE DISEASES GENENTECH SAID THE SUIT SEEKS CLARIFICATION OF WHAT CONSTITUTES A DRUG UNDER THE STANDARDS OF THE ORPHAN DRUG ACT IT SUGGESTED THAT WITHOUT THE CLARIFICATION COMPANIES THAT DEVELOP ORPHAN DRUGS MAY NOT RECOVER DEVELOPMENT COSTS DURING THE PERIOD OF MARKETING EXCLUSIVITY IT SAID LILLY'S GROWTH HORMONE AND ITS NEW GROWTH HORMONE DIFFER SLIGHTLY AND ARE PRODUCED BY DIFFERENT PROCESSES   